Conclusion
LH can be an alternative to OH for primary HCC with favorably located tumors due to the decreased intraoperative transfusion rate, shorter postoperative hospital stay, and lower 90-day readmission rate. LH will not compromise intraoperative blood loss, complication rate, morbidity, 90-day mortality rate, or long-term overall, and disease-free survival. LH stabilize the short-term and long-term outcome for primary HCC located at favorable location during the development period. Our findings can provide the evidence and confidence for institutions who want to start developing LH.